Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


ESMO 2018 in depth: Resistance mechanisms to osimertinib in patients with NSCLC and a EGFR T790M mutation

Vassiliki Papadimitrakopoulou, MD, oncologist at the MD Anderson Cancer Centre in Texas, provides information on EGFR mutations associated with resistance to osimertinib in patients with NSCLC and a T790M mutation. These results are from an analysis of the AURA3 study.

  • Sponsors

    This program is editorially independent and is financially supported by: